Research & Reports

In a phase‑3 trial, first‑line sacituzumab govitecan combined with pembrolizumab numerically extended PFS in high PD‑L1 metastatic NSCLC but did not meet pre‑specified statistical significance, nor improve OS versus pembrolizumab alone.

AbbVie’s Qulipta (atogepant) reduced migraine days versus placebo in a Phase 3 menstrual migraine study, meeting the primary endpoint and supporting label expansion.

Beeline Medicines reported its oral lupus drug afimetoran achieved the primary endpoint in a Phase 2 trial and plans pivotal studies for two lupus forms.

Within a week of U.S. approval for pancreatic cancer, daraxonrasib showed tumor shrinkage in over 30% of non‑small cell lung cancer patients in a small trial.

A UK clinical trial of 700 men on androgen deprivation therapy found that regular exercise over a year lessened treatment‑related fatigue and quality‑of‑life decline.

In the large Phase 3 Lp(a)HORIZON study of 8,323 patients, Novartis’ pelacarsen did not achieve a reduction in major cardiovascular events despite lowering Lp(a).

A Cochrane review of eight trials with over 500 adults found insufficient evidence that lumbar support belts relieve low back pain, though a modest short‑term benefit when combined with analgesics was observed.

Akeso and Summit Therapeutics reported that their PD‑1×VEGF bispecific antibody ivonescimab improved overall survival versus Merck’s Keytruda in a direct comparison trial for first‑line PD‑L1‑positive NSCLC, though market reaction was muted.

AbbVie announced that its dual-specific T-cell engager etentamig improved response rates and progression-free survival in heavily pre-treated multiple myeloma, with low CRS and infection rates.

Hanmi Pharmaceutical will unveil Phase 2 results of EPeglucoagon (HM15136), the first weekly‑dose therapy for congenital hyperinsulinism, at the ESPE 2026 meeting in Marseille.

In the global Phase 3 CARES-310 study, HLB's riboceranib‑camrelizumab combo achieved a median overall survival of 21.5 months in patients under 50, outperforming sorafenib's 15.2 months, with consistent benefit across age groups.

GC녹십자웰빙 announced that its exclusive drug candidate RZL-012 achieved primary efficacy and safety endpoints in a pivotal Phase 3 trial in China involving 480 adults with submental fat.